Cadrenal Therapeutics (CVKD) Sidoti Micro-Cap Virtual Conference summary

Key product and clinical development updates

• Tecarfarin is a novel oral vitamin K antagonist designed for stable anticoagulation in patients with cardiovascular conditions, especially those with left ventricular assist devices (LVADs).

• Multiple orphan drug and fast track designations have been secured for tecarfarin in rare cardiovascular indications, including end-stage kidney disease and atrial fibrillation.

• Tecarfarin's unique metabolism pathway offers improved stability over warfarin, addressing significant unmet needs where current therapies are inadequate.

• Extensive safety data from 11 clinical trials in over 1,000 patients supports tecarfarin's safety and efficacy profile.

• The lead clinical program targets LVAD patients, with recent Abbott-sponsored studies highlighting the inadequacy of current anticoagulation options and informing trial design.

Market opportunity and business strategy

• Tecarfarin is positioned to be the first FDA-approved anticoagulant for several rare cardiovascular conditions, filling a major market void.

• Orphan drug status and fast track designations may enable favorable pricing and accelerated approval pathways.

• Ongoing discussions with Abbott aim to explore collaboration opportunities, leveraging Abbott's leadership in LVAD devices.

• The company maintains a simple capital structure, no debt, and significant insider ownership, aligning management and investor interests.

• Business development efforts focus on partnerships with device manufacturers and targeting orphan-sized populations for commercial launch.

Clinical and regulatory outlook

• Preparations for pivotal clinical trials are underway, with site selection and community education as key focus areas.

• A meeting with the FDA is planned to finalize study design, after which clear timelines for trial readouts will be established.

• The anticipated duration from first patient enrollment to data readout is a little over two years, pending regulatory agreement.

• The company is preparing for rapid uptake post-approval, given the high unmet need and lack of alternatives.

• Educational initiatives are planned to inform prescribers about the benefits of tecarfarin over warfarin.